Drug profile · INN
bosutinib
BOSULIF
bosutinib (BOSULIF) is a tyrosine-protein kinase abl inhibitor.
EMA: approved NMPA: clinical trials Antineoplastic and immunomodulating agents (L01) L01EA04
Patents linked 0
Pipeline programs 7
News articles 1
Drug details — bosutinib
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 7
- Data quality
- 0.83
Quick answer
bosutinib (BOSULIF) is a tyrosine-protein kinase abl inhibitor.
Key facts
INN bosutinib
Brand BOSULIF
Mechanism Tyrosine-protein kinase ABL inhibitor
Target Tyrosine-protein kinase ABL1
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01EA04
Mechanism of action
Tyrosine-protein kinase ABL inhibitor
Primary target: Tyrosine-protein kinase ABL1
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is bosutinib?
bosutinib (BOSULIF) is a tyrosine-protein kinase abl inhibitor.
What is the brand name for bosutinib?
BOSULIF is a marketed brand name for bosutinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.